Review
doi: 10.1208/s12248-010-9181-5.
Epub 2010 Mar 3.
Pancreatic cancer: pathobiology, treatment options, and drug delivery
Affiliations
- PMID: 20198462
- PMCID: PMC2844509
- DOI: 10.1208/s12248-010-9181-5
Item in Clipboard
Review
Pancreatic cancer: pathobiology, treatment options, and drug delivery
AAPS J.
2010 Jun.
Abstract
Pancreatic cancer is the fourth leading cause of cancer-related deaths in the USA. The high mortality rate is partly due to lack of effective treatments. This review summarizes the pathobiology and current treatment options for pancreatic cancer. Moreover, the review discusses the opportunities of developing novel therapies for pancreatic cancer provided by the progress in understanding the genetic mutations, tumor microenvironment, cancer stem cells, and drug delivery.
Similar articles
-
Pathobiology of pancreatic cancer: implications on therapy.Expert Rev Anticancer Ther. 2016;16(2):219-27. doi: 10.1586/14737140.2016.1129276. Epub 2016 Jan 11. Expert Rev Anticancer Ther. 2016. PMID: 26652651 Review.
-
Molecular targets for the treatment of pancreatic cancer: Clinical and experimental studies.World J Gastroenterol. 2016 Jan 14;22(2):776-89. doi: 10.3748/wjg.v22.i2.776. World J Gastroenterol. 2016. PMID: 26811624 Free PMC article. Review.
-
Stem cell-directed therapies in pancreatic cancer.Curr Probl Cancer. 2013 Sep-Oct;37(5):280-6. doi: 10.1016/j.currproblcancer.2013.10.005. Epub 2013 Oct 8. Curr Probl Cancer. 2013. PMID: 24331183 Free PMC article. Review.
-
Pancreatic cancer stem cells: new understanding of tumorigenesis, clinical implications.Langenbecks Arch Surg. 2010 Jan;395(1):1-10. doi: 10.1007/s00423-009-0502-z. Epub 2009 May 7. Langenbecks Arch Surg. 2010. PMID: 19421768 Review.
-
Targeted drug delivery in pancreatic cancer.Biochim Biophys Acta. 2010 Jan;1805(1):97-104. doi: 10.1016/j.bbcan.2009.10.001. Epub 2009 Oct 22. Biochim Biophys Acta. 2010. PMID: 19853645 Free PMC article. Review.
Cited by
-
Cyclooxygenase-2 induces angiogenesis in pancreatic cancer mediated by prostaglandin E2.Oncol Lett. 2018 Jul;16(1):940-948. doi: 10.3892/ol.2018.8786. Epub 2018 May 22. Oncol Lett. 2018. PMID: 29963167 Free PMC article.
-
TRP channels and STIM/ORAI proteins: sensors and effectors of cancer and stroma cell migration.Br J Pharmacol. 2014 Dec;171(24):5524-40. doi: 10.1111/bph.12721. Epub 2014 Jul 2. Br J Pharmacol. 2014. PMID: 24724725 Free PMC article. Review.
-
Designing live bacterial therapeutics for cancer.Adv Drug Deliv Rev. 2025 Jun;221:115579. doi: 10.1016/j.addr.2025.115579. Epub 2025 Apr 12. Adv Drug Deliv Rev. 2025. PMID: 40228606 Review.
-
Irisin functions to inhibit malignant growth of human pancreatic cancer cells via downregulation of the PI3K/AKT signaling pathway.Onco Targets Ther. 2019 Sep 4;12:7243-7249. doi: 10.2147/OTT.S214260. eCollection 2019. Onco Targets Ther. 2019. PMID: 31564907 Free PMC article.
-
Intra-tumoral administration of CHST15 siRNA remodels tumor microenvironment and augments tumor-infiltrating T cells in pancreatic cancer.Mol Ther Oncol. 2024 May 3;32(2):200812. doi: 10.1016/j.omton.2024.200812. eCollection 2024 Jun 20. Mol Ther Oncol. 2024. PMID: 38799652 Free PMC article.
References
-
- American Cancer Society. Estimated new cancer cases and deaths by sex, US. http://www.cancer.org. Accessed 20 Dec 2009.
-
- Michaud DS. Epidemiology of pancreatic cancer. Minerva Chir. 2004;59:99–111. - PubMed
-
- Gutt R, Liauw SL, Weichselbaum RR. Adjuvant radiotherapy for resected pancreatic cancer: a lack of benefit or a lack of adequate trials? Nat Clin Pract Gastroenterol Hepatol. 2009;6:38–46. - PubMed
-
- Mahalingam D, Kelly KR, Swords RT, Carew J, Nawrocki ST, Giles FJ. Emerging drugs in the treatment of pancreatic cancer. Expert Opin Emerg Drugs. 2009;14:311–28. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
